Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in total population randomised compared with placebo compared (low certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in screened population · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in screened population compared with placebo compared (moderate certainty).
1 finding from 1 review
Improvement in vertigo frequency · Ménière’s disease
Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).
2 findings from 1 review
Change in vertigo (global score) · Ménière’s disease
1 finding from 1 review
Change in vertigo frequency · Ménière’s disease
3 findings from 1 review
no estimate extracted
3 studies · 472 participants
Low
no estimate extracted
1 study · 20 participants
Very low
no estimate extracted
1 study · 18 participants
Very low
Serious adverse events · Ménière’s disease
It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether topical (intranasal) steroids changes adverse event: systemic corticosteroid side effects compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Hearing · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether topical (intranasal) steroids changes presence/persistence of OME (short‐term); assumed ICC = 0.5 compared with no treatment (very low certainty).
1 finding from 1 review
RR 0.72 [0.57, 0.91]
Studies not reported
Very low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
Intratympanic corticosteroids may leads to higher proportion of patients whose hearing is improved compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in final hearing threshold determined by PTA (a lower value represents… compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found